Objective: We prospectively evaluated the fluctuation of lamotrigine (LTG) clearance during the menstrual cycle. We also assessed the effect of postmenopausal status and investigated in detail the effect of oral contraceptives (OCs) on LTG clearance. Methods: Three groups of women with epilepsy using LTG monotherapy were evaluated. Women in the first group (n = 7) had a regular cycle and did not use OCs; the second group used a 1-phase combined OC (n = 7), and the third group (n = 7) was postmenopausal. Two menstrual cycles or at least 2 months (postmenopausal women) were assessed, monitoring LTG levels every other day. Results: The mean apparent LTG clearance in women of reproductive age not using OCs was 49 (SD 22.6, range 20.4–83.5) L/24 hours. No significant effect of endogenous hormones on LTG clearance was found. In women using OCs, the mean LTG clearance was 126 (SD 60.2, range 44.3–205) L/24 hours. There was an increase in LTG levels during the pill-free week, with maximum levels 54% (range 29%–129%) higher than baseline levels. LTG levels decreased to the baseline value within a mean of 8 days of starting OC use (SD 3.7, range 2.5–16.5). In the postmenopausal women, the mean clearance was 82 (SD 38.4, range 35.9–125) L/24 hours. Conclusions: We observed a higher mean lamotrigine (LTG) clearance in postmenopausal women compared with young women not using oral contraceptives (OCs) and confirmed that OC use may have a strong effect on LTG clearance. There was no significant fluctuation of LTG clearance during the menstrual cycle.
Little is known about pregnancy‐induced alterations in the pharmacokinetics of the newer antiepileptic drugs, especially when used in combinations. Two women receiving combination therapy of lamotrigine (LTG) and oxcarbazepine (OXC) were followed prospectively during pregnancy and puerperium. Steady‐state concentrations of LTG and the active metabolite of OXC, 10‐hydroxycarbazepine (MHD), were measured at regular intervals using a dried blood spot method, and clearances were calculated. A strong effect of pregnancy on the clearance of both LTG and MHD was seen. An increase in seizure frequency occurred in both women. This stresses the importance of therapeutic drug monitoring of LTG and MHD during pregnancy. In case of breakthrough seizures or increased seizure frequency, dosage adjustment of both drugs may be required.
Objectives To evaluate prospectively the influence of cyclic oral contraceptive (OC) use on lamotrigine (LTG) serum levels when used in combination therapy. Methods Women with epilepsy using LTG in combination with valproate (VPA; n=7), carbamazepine (CBZ; n=3) or oxcarbazepine (OXC; n=1) were evaluated during two periods of 28days cyclic OC use, monitoring antiepileptic drug (AED) levels every other day with the dried blood spot sampling method. Results were compared with women on LTG monotherapy and OCs (n=12). Pharmacokinetic analysis was performed using NONMEM software. Results Mean study population value of LTG clearance estimated by the final model was 3.17l/h. Introduction of covariates for comedication (VPA, CBZ, OXC and OC) significantly reduced the between-subject variability. A significant influence of OC comedication on LTG clearance was seen in both LTG monotherapy (clearance with OC 4.02 +/- 0.38l/h, OC-free week 3.03 +/- 0.39l/h) and in LTG-CBZ combination (clearance with OC 4.95 +/- 0.15l/h, OC-free week 4.15 +/- 0.26l/h). No influence of OC was found in LTG-VPA combination (clearance with OC 0.99 +/- 0.16l/h, OC-free week 0.90 +/- 0.15l/h). Conclusions Adding OCs to LTG monotherapy or the combination LTG-CBZ significantly increased the LTG clearance and thus reduced LTG serum levels. In the combination LTG-CBZ, OCs had a non-significant effect on CBZ clearance. No significant influence of cyclic OC use on LTG or VPA clearance was found when these AEDs were used in combination.
23 March 2015 in British Journal of Clinical Pharmacology
Optimale behandeling van epilepsie tijdens de zwangerschap is belangrijk voor zowel moeder als kind. De dosering van anti-aanvalsmedicatie moet soms worden aangepast vanwege een snellere eliminatie dan gebruikelijk. In een uitgebreide studie werd de daling van serumconcentraties van levetiracetam en de consequenties hiervan voor de aanvalsfrequentie onderzocht.